Revance Therapeutics Inc.
www.revance.com
Latest From Revance Therapeutics Inc.
Finance Watch: Biopharma Stocks See Big Post-IPO Jumps
Public Company Edition: Five out of six drug developers and a CRO have seen their values spike immediately after going public this month. Also, Moderna floats a $500m offering, Revance proposes a $20m note sale, and Nestle invests another $200m in Aimmune.
J.P. Morgan Notebook Day 4: Novartis CEO Weighs In On AI, Sangamo’s Next Steps And More
Additional highlights from the J.P. Morgan Healthcare Conference, including Takeda’s partnering outlook, Sage’s guidance on Zulresso sales, Frequency’s next steps for its hearing loss drug and Revance’s preparations to take on the aesthetics market.
J.P. Morgan Notebook Day 4: Novartis CEO Weighs In On AI, Sangamo’s Next Steps And More
Additional highlights from the J.P. Morgan Healthcare Conference, including Takeda’s partnering outlook, Sage’s guidance on Zulresso sales, Frequency’s next steps for its hearing loss drug and Revance’s preparations to take on the aesthetics market.
AbbVie Updates Exec Team, Creates A Separate Aesthetics Business Unit
The only addition to AbbVie’s leadership after it closes the $63bn acquisition of Allergan will be Carrie Strom, who will lead the Allergan Aesthetics business.
Company Information
- Industry
-
Biotechnology
- Large Molecule
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
- Site Specific
- Topical Delivery
-
Drug Delivery
- Therapeutic Areas
- Dermatology
- Gynecological, Urological
- Musculoskeletal & Connective Tissue Disorders
- Neurology, Nervous System
- Alias(es)
- Essentia Biosystems Inc.
- Ownership
- Public
- Headquarters
-
Worldwide
-
North America
-
USA
-
USA
-
North America
- Parent & Subsidiaries
- Revance Therapeutics Inc.
- Senior Management
-
Mark J Foley, Pres. & CEO
Tobin Schilke, CFO
Abhay Joshi, PhD, COO
Taryn Conway, VP, Mktg. - Contact Info
-
Revance Therapeutics Inc.
Phone: (510) 742-3400
7555 Gateway Blvd.
Newark, CA 94560
USA
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice